These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 27190322)

  • 21. New therapies for chronic hepatitis B.
    Bitton Alaluf M; Shlomai A
    Liver Int; 2016 Jun; 36(6):775-82. PubMed ID: 26854115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meeting the Challenge of Eliminating Chronic Hepatitis B Infection.
    Revill PA; Penicaud C; Brechot C; Zoulim F
    Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 30939846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New therapeutic agents for chronic hepatitis B.
    Brahmania M; Feld J; Arif A; Janssen HL
    Lancet Infect Dis; 2016 Feb; 16(2):e10-21. PubMed ID: 26795693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.
    Guo JT; Guo H
    Antiviral Res; 2015 Oct; 122():91-100. PubMed ID: 26272257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of chronic hepatitis B.
    Loomba R; Liang TJ
    Antivir Ther; 2007; 12 Suppl 3():H33-41. PubMed ID: 18284181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B virus therapy: What's the future holding for us?
    Manzoor S; Saalim M; Imran M; Resham S; Ashraf J
    World J Gastroenterol; 2015 Nov; 21(44):12558-75. PubMed ID: 26640332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HBV cure: why, how, when?
    Levrero M; Testoni B; Zoulim F
    Curr Opin Virol; 2016 Jun; 18():135-43. PubMed ID: 27447092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations.
    Yuen MF; Ahn SH; Chen DS; Chen PJ; Dusheiko GM; Hou JL; Maddrey WC; Mizokami M; Seto WK; Zoulim F; Lai CL
    J Clin Gastroenterol; 2016 Apr; 50(4):286-94. PubMed ID: 26840752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection.
    Pei Y; Wang C; Yan SF; Liu G
    J Med Chem; 2017 Aug; 60(15):6461-6479. PubMed ID: 28383274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunopathogenesis of chronic hepatitis B.
    Balmasova IP; Yushchuk ND; Mynbaev OA; Alla NR; Malova ES; Shi Z; Gao CL
    World J Gastroenterol; 2014 Oct; 20(39):14156-71. PubMed ID: 25339804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune balance in Hepatitis B Infection: Present and Future Therapies.
    Vyas AK; Jindal A; Hissar S; Ramakrishna G; Trehanpati N
    Scand J Immunol; 2017 Jul; 86(1):4-14. PubMed ID: 28387980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging pipeline drugs for hepatitis B infection.
    Cox N; Tillmann H
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential Drug Targets Against Hepatitis B Virus Based on Both Virus and Host Factors.
    Zhang BY; Chai DP; Wu YH; Qiu LP; Zhang YY; Ye ZH; Yu XP
    Curr Drug Targets; 2019; 20(16):1636-1651. PubMed ID: 31362671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA.
    Kumar R; Pérez-Del-Pulgar S; Testoni B; Lebossé F; Zoulim F
    Liver Int; 2016 Jan; 36 Suppl 1():72-7. PubMed ID: 26725901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA.
    Ahmed M; Wang F; Levin A; Le C; Eltayebi Y; Houghton M; Tyrrell L; Barakat K
    Drug Discov Today; 2015 May; 20(5):548-61. PubMed ID: 25622780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic hepatitis B: A wave of new therapies on the horizon.
    Block TM; Rawat S; Brosgart CL
    Antiviral Res; 2015 Sep; 121():69-81. PubMed ID: 26112647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
    Lau GK; Cooksley H; Ribeiro RM; Powers KA; Shudo E; Bowden S; Hui CK; Anderson J; Sorbel J; Mondou E; Rousseau F; Lewin S; Perelson AS; Locornini S; Naoumov NV
    Antivir Ther; 2007; 12(5):705-18. PubMed ID: 17713154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis B Virus Cure: Targets and Future Therapies.
    Lee HW; Lee JS; Ahn SH
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection.
    Brunetto MR; Cavallone D; Oliveri F; Moriconi F; Colombatto P; Coco B; Ciccorossi P; Rastelli C; Romagnoli V; Cherubini B; Teilum MW; Blondal T; Bonino F
    PLoS One; 2014; 9(10):e110782. PubMed ID: 25350115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Best Practice in Hepatitis B Management and Understanding Long-term Prospects for Cure.
    Yardeni D; Chang KM; Ghany MG
    Gastroenterology; 2023 Jan; 164(1):42-60.e6. PubMed ID: 36243037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.